Τίτλος:
Antihypertensive Drugs and Risk of Cancer: Between Scylla and Charybdis
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Antihypertensive drugs namely angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, beta blockers, and diuretics are among the most clearly documented regimens worldwide with an overall cardioprotective benefit. Given that malignancy is the second leading cause of mortality, numerous observational studies aimed to investigate the carcinogenic potential of these agents with conflicting results. The purpose of this review was to summarize current data in an effort to explore rare side effects and new mechanisms linking antihypertensive drugs with the risk of developing cancer. © 2020 American Journal of Hypertension, Ltd 2020. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Συγγραφείς:
Sanidas, E.
Velliou, M.
Papadopoulos, D.
Fotsali, A.
Iliopoulos, D.
Mantzourani, M.
Toutouzas, K.
Barbetseas, J.
Περιοδικό:
American Journal of Hypertension
Εκδότης:
Oxford University Press
Λέξεις-κλειδιά:
alpha adrenergic receptor blocking agent; antihypertensive agent; beta adrenergic receptor blocking agent; calcium channel blocking agent; diuretic agent; mineralocorticoid receptor; renin angiotensin inhibitor; steroid hormone receptor blocking agent; unclassified drug; alpha adrenergic receptor blocking agent; angiotensin receptor antagonist; antihypertensive agent; beta adrenergic receptor blocking agent; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; diuretic agent; mineralocorticoid antagonist, antihypertensive therapy; breast cancer; cancer risk; digestive system cancer; human; hypertension; lung cancer; malignant neoplasm; ovary cancer; priority journal; prostate cancer; renal cell carcinoma; Review; risk factor; skin cancer; breast tumor; female; gastrointestinal tumor; hypertension; kidney tumor; lung tumor; male; neoplasm; ovary tumor; prostate tumor; protection; renal cell carcinoma; skin tumor, Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Breast Neoplasms; Calcium Channel Blockers; Carcinoma, Renal Cell; Diuretics; Female; Gastrointestinal Neoplasms; Humans; Hypertension; Kidney Neoplasms; Lung Neoplasms; Male; Mineralocorticoid Receptor Antagonists; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Protective Factors; Risk Factors; Skin Neoplasms
